COHEN & STEERS INC (CNS) Fundamental Analysis & Valuation

NYSE:CNS • US19247A1007

Current stock price

68.94 USD
+0.79 (+1.16%)
At close:
68.94 USD
0 (0%)
After Hours:

This CNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. CNS Profitability Analysis

1.1 Basic Checks

  • In the past year CNS was profitable.
  • In the past year CNS has reported a negative cash flow from operations.
  • CNS had positive earnings in each of the past 5 years.
  • CNS had a positive operating cash flow in 4 of the past 5 years.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 17.48%, CNS belongs to the top of the industry, outperforming 92.89% of the companies in the same industry.
  • CNS has a better Return On Equity (27.27%) than 91.21% of its industry peers.
  • CNS's Return On Invested Capital of 20.96% is amongst the best of the industry. CNS outperforms 96.65% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CNS is significantly above the industry average of 7.30%.
Industry RankSector Rank
ROA 17.48%
ROE 27.27%
ROIC 20.96%
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 27.66%, CNS is in the better half of the industry, outperforming 67.78% of the companies in the same industry.
  • In the last couple of years the Profit Margin of CNS has grown nicely.
  • CNS's Operating Margin of 31.68% is fine compared to the rest of the industry. CNS outperforms 60.25% of its industry peers.
  • In the last couple of years the Operating Margin of CNS has declined.
  • With an excellent Gross Margin value of 86.84%, CNS belongs to the best of the industry, outperforming 91.63% of the companies in the same industry.
  • CNS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.68%
PM (TTM) 27.66%
GM 86.84%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CNS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CNS has more shares outstanding
  • CNS has more shares outstanding than it did 5 years ago.
  • CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 7.79 indicates that CNS is not in any danger for bankruptcy at the moment.
  • CNS's Altman-Z score of 7.79 is amongst the best of the industry. CNS outperforms 92.89% of its industry peers.
  • There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.79
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • CNS has a Current Ratio of 0.98. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CNS has a Current ratio (0.98) which is comparable to the rest of the industry.
  • CNS has a Quick Ratio of 0.98. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of CNS (0.98) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.98
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CNS Growth Analysis

3.1 Past

  • CNS shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.37%.
  • The Earnings Per Share has been growing slightly by 3.74% on average over the past years.
  • CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.16%.
  • The Revenue has been growing slightly by 5.73% on average over the past years.
EPS 1Y (TTM)5.37%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%5.33%
Revenue 1Y (TTM)9.16%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%8.31%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.32% on average over the next years.
  • The Revenue is expected to grow by 3.01% on average over the next years.
EPS Next Y10.23%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
EPS Next 5Y7.32%
Revenue Next Year4.19%
Revenue Next 2Y4.28%
Revenue Next 3Y-0.11%
Revenue Next 5Y3.01%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

2

4. CNS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 21.96, the valuation of CNS can be described as rather expensive.
  • Based on the Price/Earnings ratio, CNS is valued a bit more expensive than 64.02% of the companies in the same industry.
  • CNS is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.91, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 18.12, the valuation of CNS can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CNS is on the same level as its industry peers.
  • CNS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.99, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 21.96
Fwd PE 18.12
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CNS indicates a somewhat cheap valuation: CNS is cheaper than 69.87% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.93
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)2.15
PEG (5Y)5.87
EPS Next 2Y10.78%
EPS Next 3Y3.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. CNS Dividend Analysis

5.1 Amount

  • CNS has a Yearly Dividend Yield of 3.99%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 6.53, CNS has a dividend in line with its industry peers.
  • CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 3.99%

5.2 History

  • The dividend of CNS decreases each year by -0.61%.
  • CNS has paid a dividend for at least 10 years, which is a reliable track record.
  • CNS has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)-0.61%
Div Incr Years3
Div Non Decr Years3
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • 82.84% of the earnings are spent on dividend by CNS. This is not a sustainable payout ratio.
DP82.84%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CNS Fundamentals: All Metrics, Ratios and Statistics

COHEN & STEERS INC

NYSE:CNS (4/28/2026, 8:22:08 PM)

After market: 68.94 0 (0%)

68.94

+0.79 (+1.16%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)04-16
Earnings (Next)07-15
Inst Owners56.08%
Inst Owner Change0.55%
Ins Owners22.61%
Ins Owner Change5.62%
Market Cap3.54B
Revenue(TTM)564.83M
Net Income(TTM)153.22M
Analysts48
Price Target66.3 (-3.83%)
Short Float %3.17%
Short Ratio2.41
Dividend
Industry RankSector Rank
Dividend Yield 3.99%
Yearly Dividend2.5
Dividend Growth(5Y)-0.61%
DP82.84%
Div Incr Years3
Div Non Decr Years3
Ex-Date03-09
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.25%
Min EPS beat(2)-0.99%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-1.02%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)2
Avg EPS beat(8)-1.07%
EPS beat(12)4
Avg EPS beat(12)0.08%
EPS beat(16)8
Avg EPS beat(16)0.68%
Revenue beat(2)1
Avg Revenue beat(2)0.17%
Min Revenue beat(2)-0.52%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.18%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)-15.58%
EPS NQ rev (1m)3.85%
EPS NQ rev (3m)3.18%
EPS NY rev (1m)1.3%
EPS NY rev (3m)1.6%
Revenue NQ rev (1m)2.09%
Revenue NQ rev (3m)1.57%
Revenue NY rev (1m)-2.89%
Revenue NY rev (3m)-3.83%
Valuation
Industry RankSector Rank
PE 21.96
Fwd PE 18.12
P/S 6.4
P/FCF N/A
P/OCF N/A
P/B 6.3
P/tB 6.54
EV/EBITDA 17.93
EPS(TTM)3.14
EY4.55%
EPS(NY)3.8
Fwd EY5.52%
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS10.78
BVpS10.94
TBVpS10.55
PEG (NY)2.15
PEG (5Y)5.87
Graham Number27.795 (-59.68%)
Profitability
Industry RankSector Rank
ROA 17.48%
ROE 27.27%
ROCE 27.12%
ROIC 20.96%
ROICexc 27.04%
ROICexgc 30.2%
OM 31.68%
PM (TTM) 27.66%
GM 86.84%
FCFM N/A
ROA(3y)17.87%
ROA(5y)24.39%
ROE(3y)30.23%
ROE(5y)44.84%
ROIC(3y)23.28%
ROIC(5y)32.89%
ROICexc(3y)33.62%
ROICexc(5y)61.08%
ROICexgc(3y)38.82%
ROICexgc(5y)75.29%
ROCE(3y)30.11%
ROCE(5y)42.55%
ROICexgc growth 3Y-33.24%
ROICexgc growth 5Y-15.16%
ROICexc growth 3Y-30.82%
ROICexc growth 5Y-13.86%
OM growth 3Y-4.66%
OM growth 5Y-2.01%
PM growth 3Y-3.48%
PM growth 5Y8.65%
GM growth 3Y0.67%
GM growth 5Y0.08%
F-Score3
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 51.04%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.98
Altman-Z 7.79
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)421.2%
Cap/Depr(5y)277.41%
Cap/Sales(3y)4.98%
Cap/Sales(5y)3.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.37%
EPS 3Y-5.81%
EPS 5Y3.74%
EPS Q2Q%5.33%
EPS Next Y10.23%
EPS Next 2Y10.78%
EPS Next 3Y3.87%
EPS Next 5Y7.32%
Revenue 1Y (TTM)9.16%
Revenue growth 3Y-0.12%
Revenue growth 5Y5.73%
Sales Q2Q%8.31%
Revenue Next Year4.19%
Revenue Next 2Y4.28%
Revenue Next 3Y-0.11%
Revenue Next 5Y3.01%
EBIT growth 1Y1.51%
EBIT growth 3Y-4.78%
EBIT growth 5Y3.6%
EBIT Next Year0.51%
EBIT Next 3Y0.2%
EBIT Next 5Y5.6%
FCF growth 1Y-248.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-224.57%
OCF growth 3YN/A
OCF growth 5YN/A

COHEN & STEERS INC / CNS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CNS.


What is the valuation status for CNS stock?

ChartMill assigns a valuation rating of 2 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.


What is the profitability of CNS stock?

COHEN & STEERS INC (CNS) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for CNS stock?

The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 21.96 and the Price/Book (PB) ratio is 6.3.


What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 10.23% in the next year.